Search

Search Constraints

You searched for: Author/Creator Hassenstab, Jason

Search Results

31. Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease. Issue 3 (25th August 2018)

32. Enabling Technologies for Personalized and Precision Medicine. Issue 5 (May 2020)

33. Evaluation of dose‐dependent treatment effects after mid‐trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Issue 1 (3rd November 2022)

34. Examining the Complicated Relationship Between Depressive Symptoms and Cognitive Impairment in Preclinical Alzheimer Disease. (January 2019)

35. F4‐03‐02: The Dominantly Inherited Alzheimer Network Trials Unit. (1st July 2016)

36. F5‐02‐01: COGNITIVE TRAJECTORIES IN DIAN: RELATIONSHIPS WITH SYMPTOM ONSET, MUTATION TYPES, AND CLINICAL STATUS. (1st July 2016)

37. F5‐02‐03: BDNF VAL66MET Moderates Cognitive Impairment, Neuronal Dysfunction and TAU in Preclinical Autosomal Dominant Alzheimer's Disease. (1st July 2016)

38. Gantenerumab in‐depth outcomes: Results of the DIAN‐TU prevention trial of solanezumab and gantenerumab in dominantly inherited AD. (7th December 2020)

40. IC‐P‐042: RESTING‐STATE FUNCTIONAL CONNECTIVITY ASSOCIATES WITH PATHOLOGICAL BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. (1st July 2006)